NCT06815237

Brief Summary

The research study is being conducted to better understand the effects of ketones and alcohol on brain functioning and brain metabolism. Participants will be asked to undergo three identical MRI visits after three single-dose interventions: (1) drink a ketone supplement drink, (2) drink an alcoholic beverage, (3) no intervention. These interventions will be randomly assigned (meaning everyone receives all 3 interventions, but in different orders).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
37mo left

Started May 2025

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
May 2025May 2029

First Submitted

Initial submission to the registry

February 3, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 7, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 13, 2025

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2029

Last Updated

March 25, 2026

Status Verified

March 1, 2026

Enrollment Period

4.1 years

First QC Date

February 3, 2025

Last Update Submit

March 23, 2026

Conditions

Keywords

ketone supplement

Outcome Measures

Primary Outcomes (3)

  • To examine the acute effects of ketone supplements compared to no intervention on Nicotinamide adenine dinucleotide levels in the brain.

    Use MRI imaging to measure the amount of Nicotinamide adenine dinucleotide levels in the brain measured in mmol/L in participants after receiving ketone supplement intervention compared to no intervention.

    60 minutes

  • To examine the acute effects of ketone supplements compared to no intervention on brain Glutamate levels.

    Use MRI imaging to measure the amount of Glutamate levels in the brain measured in mmol/L in participants after receiving ketone supplement intervention compared to no intervention.

    45 minutes

  • To examine the acute effects of ketone supplements compared to no intervention on brain Gamma-aminobutyric acid levels.

    Use MRI imaging to measure the amount of Gamma-aminobutyric acid levels in the brain measured in mmol/L in participants after receiving ketone supplement intervention compared to no intervention.

    75 minutes

Secondary Outcomes (3)

  • To examine the acute effects of alcohol (dose adjusted by weight) compared to no intervention on Nicotinamide adenine dinucleotide levels in the brain.

    60 minutes

  • To examine the acute effects of alcohol (dose adjusted by weight) compared to no intervention on brain Glutamate levels.

    45 minutes

  • To examine the acute effects of alcohol (dose adjusted by weight) compared to no intervention on brain Gamma-aminobutyric acid levels.

    75 minutes

Study Arms (3)

Ketone Supplement

EXPERIMENTAL

Subjects will receive ketone supplement once by mouth, 20g of kentones.

Dietary Supplement: Kenetik

Alcohol beverage

EXPERIMENTAL

Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.050%

Other: Alcohol beverage

No Intervention

NO INTERVENTION

No intervention will be given

Interventions

KenetikDIETARY_SUPPLEMENT

Ketone supplement is randomly given once.

Also known as: D-Beta-hydroxybutyric acid and R-1,3 butanediol, Ketone supplement
Ketone Supplement

Alcohol beverage is randomly given once. Participants will receive the alcohol beverage that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.050%

Also known as: Ethanol
Alcohol beverage

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to provide written informed consent and commit to completing study procedures.
  • Reported on at least one day in the month before consent of consuming 2 or more standard alcoholic drinks on a single day.

You may not qualify if:

  • Unwilling or unable to refrain from the use of psychoactive medications, medication that may affect study results, and or alcohol, within 24 hours of the Alcohol lab, and MRI procedures (self-report, medical history, UDS, and breathalyzer).
  • Current DSM-5 diagnosis of a major psychiatric disorder (other than marijuana and nicotine use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.
  • Currently taking a medication that could interfere with study participation or make it hazardous for the subject to participate. (e.g., anticholinergics; antipsychotics; psychotropic drugs not otherwise specified)
  • A current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation that could interfere with study participation or make it hazardous for the subject to do so (e.g., bleeding disorder, pancreatitis, epilepsy, liver disease, kidney disease, or diabetes as determined by history and clinical exam); ALAT or ASAT concentration greater than 3 times the upper limit of normal (ULN), or bilirubin above the ULN. (Note-abnormal laboratory tests during screening may be repeated once).
  • Current, major gastrointestinal (GI) diseases, such as: GERD, Crohn's disease, Irritable bowel syndrome, Ulcerative colitis, Celiac disease Diverticulitis, or other clinically significant physical disease that may interfere with the intake of the Ketone Supplement based on medical history, and evaluation of the Study Physician.
  • Head trauma with loss of consciousness for more than 30 minutes (self-report, medical history).
  • Pregnant or breast-feeding
  • Weight greater than 250lbs (Need to cap amount of alcohol give based on weight to individuals).
  • Self-reported claustrophobia
  • Contraindications to MRI (e.g., metal in the body that cannot be removed and is not MRI compatible).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Studies of Addiction

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

MeSH Terms

Conditions

KetosisAlcohol Drinking

Interventions

Ethanol

Condition Hierarchy (Ancestors)

AcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesDrinking BehaviorBehavior

Intervention Hierarchy (Ancestors)

AlcoholsOrganic Chemicals

Study Officials

  • Corinde Wiers, Ph.D.

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Participants will randomly receive each intervention once: ketone supplement, alcohol beverage, and no intervention.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 3, 2025

First Posted

February 7, 2025

Study Start

May 13, 2025

Primary Completion (Estimated)

May 31, 2029

Study Completion (Estimated)

May 31, 2029

Last Updated

March 25, 2026

Record last verified: 2026-03

Locations